For the past 15 years, standard disease-modifying therapies (DMTs) for multiple sclerosis (MS) have been available only as injections, which has limited adherence for many patients. Several new drugs, including monoclonal antibodies and orally administered agents, are currently being studied in MS. As well as having a novel mechanism of action, oral drugs hold the promise of improving patient compliance and adherence to therapy.